Phase I Study to Evaluate the Tolerability, Pharmacokinetics, Immunogenicity, Safety of Dose Escalation and Preliminary Efficacy of GR1401 in Patients with Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Interventions: Case series:GR1401 monoclonal antibody Primary outcome(s): Maximum tolerated dose;Dose limiting toxicity;Safety assessment Study Design: Case series
创建时间：
2017-08-15
